Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
iCAD, a leader in medical technology, has initiated the GLIOX trial, targeting recurrent glioblastoma using the Xoft® Axxent® Electronic Brachytherapy System. This significant milestone took place at Providence Saint John’s Health Center, led by renowned oncologist Santosh Kesari. The trial aims to compare Xoft IORT with Avastin against traditional treatments, building on promising data from earlier studies. Results showed patients receiving Xoft IORT had longer survival rates and fewer complications, signaling potential advancements in brain tumor therapy.
NASHUA, N.H., Dec. 6, 2021 -- iCAD, a leader in cancer detection and therapy solutions, announced that Stacey Stevens, President and incoming CEO, will present at Oppenheimer’s Imagine AI + Healthcare Investor Summit. The presentation is scheduled for December 7, 2021, from 11:00 a.m. to 11:20 a.m. ET. This event, organized by Oppenheimer in collaboration with the Alliance for AI in Healthcare, highlights advancements in AI technology within healthcare.
For more information, visit www.icadmed.com.
iCAD appointed Stacey Stevens as President and CEO, effective March 1, 2022. Stevens, previously the company's President, joins the Board of Directors, while Michael Klein continues as Chairman. The Board highlighted Stevens' focus on driving change and innovation at a crucial growth phase for iCAD, particularly with recent technology launches in cancer detection and therapy. Stevens aims to enhance patient care and shareholder value through the company's advanced solutions.
iCAD (NASDAQ: ICAD) announced that its advanced breast cancer detection software, ProFound AI, will be highlighted in three scientific presentations at the RSNA 2021 meeting. Key studies focus on ProFound AI's effectiveness in improving cancer detection outcomes in digital breast tomosynthesis (DBT) screenings. Presentations will discuss AI's role in identifying aggressive lesions and its real-world impact on detection rates. Notably, ProFound AI reduces reading time by 52.7% and enhances radiologist sensitivity by 8%. The company continues to advance its technology for better patient care in breast health.
iCAD, Inc. (NASDAQ: ICAD), a leader in medical technology, announced its participation in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021, starting at 9:00 AM ET. The company's management will be available for virtual one-on-one meetings with registered investors. iCAD specializes in innovative solutions for cancer detection and therapy. For further details regarding the conference, interested parties can visit Craig-Hallum.com.
iCAD (NASDAQ: ICAD) will host its 2nd annual virtual investor webinar on November 18, 2021, from 3:00 to 4:30 PM ET.
The event will feature leading experts discussing iCAD’s Breast Health Solutions and the innovative Xoft System, enhancing clinical efficiency and patient outcomes.
Key speakers include Angela Fried, MD, and Sally Grady, among others. The webinar will showcase ProFound® AI, a groundbreaking technology for breast cancer detection with proven efficiency improvements.
Registration is available via iCAD's official website.
iCAD reported third quarter 2021 revenues of $9.4 million, marking a 31% increase year-over-year and a 20% sequential rise. Detection revenue grew by 26% while therapy revenue rose 10%. Notably, the Xoft® product revenue saw a 34% sequential increase. Despite these gains, the company experienced a net loss of $2.2 million. The nine-month revenues totaled $25.8 million, up 34% compared to 2020. CEO Mike Klein highlighted ongoing market demand and product launches as critical drivers for future growth.
iCAD (NASDAQ: ICAD) will announce its third-quarter financial results on November 9, 2021, after market close. A conference call is scheduled for 4:30 PM ET, providing an opportunity for investors to gain insights into the company's performance in cancer detection and therapy solutions. The domestic and international call-in numbers are provided, along with a conference ID and a link for the webcast. iCAD continues to position itself as a leader in the medical technology sector.
iCAD, a leader in medical technology, will present its advanced ProFound AI for 2D Mammography at the Journées Francophones de Radiologie in Paris from October 8-11, 2021. This new version shows significant performance improvements: up to 4% increased sensitivity and 10% improved specificity, alongside 40% faster processing times. A new product, ProFound AI Risk, now estimates short-term breast cancer risk based solely on screening mammograms. This technology aims to enhance breast cancer detection and empower women to better manage their healthcare.
iCAD, a leader in medical technology, has launched ProFound AI Risk and an updated PowerLook Density Assessment, enhancing breast cancer screening capabilities. The ProFound AI Risk tool offers personalized short-term breast cancer risk estimations from mammogram images, integrating ethnic data for inclusive screening. This innovation aims to reduce unnecessary procedures and improve patient outcomes. Meanwhile, PowerLook Density Assessment automates breast density evaluation, addressing subjectivity in assessments. These advancements are expected to support clinicians as they navigate post-COVID challenges in breast cancer detection.